Editor | Curator

Advertisment

Interview: Dr. Deborah Nash, Ibogaine and Miami Based DemeRX.

Partnered with ATAI Life Sciences ATAI. Amazing Interview. "I said there's no way that you can take one dose of Ibogaine and have this complete reset, to use the...

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical (BWVI). Forbes

Mike Zapolin, Kevein Harrington and CEO Chad Harman Another Shark Tank original has invested in the psychedelic industry. Kevin Harrington, the creator of the...

Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. (Ketamine.)

Above: Lamar Odom and Psychedelic Advocate Mike Zappy Zapolin. We’re Calling a Sector Bottom, and Psycheceutical (BWVI) as Our Favorite. We launched...

Ketamine and Yale University

Depression is one of the most common and most debilitating mental health disorders, affecting some 17 million adults in the US. It also continues to be a misunderstood, often hard-to-treat...

Johns Hopkins Receives $20M From Roland R. Griffiths Ph.D. Professorship Fund For Psychedelic Research

John Hopkins Center for Psychedelic and Consciousness Research Johns Hopkins University academics just a got a boost in their funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early stages of a recovery (our opinion) gaining 94%...

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia Phase I trial will study 20 people to...

Editor | Curator

Advertisment